Sarcoma News

A 45-year-old woman reported she had experienced bloating and felt lower abdominal pressure for the past 3 months.

CHICAGO — Gary K. Schwartz, MD, chief of hematology and oncology at Columbia University Medical Center, evaluates how immunotherapy can treat the various subtypes of sarcomas at the ASCO Annual Meeting.

James P. Allison, PhD, chair of the department of immunology and executive director of the immunotherapy platform at MD Anderson Cancer Center in Houston, discusses toxicities related to immune-based strategies to treat cancer.

CHICAGO — Candace Johnson, PhD, president and CEO of Roswell Park Cancer Institute, discusses how research in immunotherapy and genomics can lead to tailored personalized treatments at the ASCO Annual Meeting.

CHICAGO — Dawn L. Hershman, MD, MS, associate professor of medicine at Columbia University Medical Center, reviews study results that identified comorbidities and lifestyle-related factors that can predict chemotherapy-induced peripheral neuropathy risk at the ASCO Annual Meeting.

The use of NY-ESO-1-specific T cells for the treatment of synovial sarcoma and myxoid/round-cell liposarcoma demonstrated evidence of clinical activity and disease regression, according to research Seth M. Pollack, MD, of Fred Hutchinson Cancer Research Center, presented at the ASCO Annual Meeting.

Employees of SLACK Incorporated — publisher of HemOnc Today — wore white today in support of White Out Cancer Day.

Coffee no longer should be classified as carcinogenic to humans, according to a working group from WHO’s International Agency for Research on Cancer.

CHICAGO — Gary K. Schwartz, MD, chief of hematology and oncology at Columbia University Medical Center, discusses research that evaluates treatments for sarcoma that target receptor tyrosine kinases at the ASCO Annual Meeting.

This year’s ASCO Annual Meeting featured the theme “Collective wisdom: The future of patient-centered care and research.”